Fu T - Search Results

1

CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D, He Q, Sun J, Sharma P. Chen H, et al. Among authors: fu t. Cancer Immunol Res. 2014 Feb;2(2):167-76. doi: 10.1158/2326-6066.CIR-13-0155. Epub 2013 Nov 19. Cancer Immunol Res. 2014. PMID: 24778280 Free PMC article. Clinical Trial.

2

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.

Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Shi LZ, et al. Among authors: fu t. Cancer Immunol Res. 2019 Nov;7(11):1803-1812. doi: 10.1158/2326-6066.CIR-18-0873. Epub 2019 Aug 29. Cancer Immunol Res. 2019. PMID: 31466995

3

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

Fu T, He Q, Sharma P. Fu T, et al. Cancer Res. 2011 Aug 15;71(16):5445-54. doi: 10.1158/0008-5472.CAN-11-1138. Epub 2011 Jun 27. Cancer Res. 2011. PMID: 21708958

4

ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.

Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. Metzger TC, et al. Among authors: fu t. Cancer Res. 2016 Jul 1;76(13):3684-9. doi: 10.1158/0008-5472.CAN-15-3412. Epub 2016 May 4. Cancer Res. 2016. PMID: 27197182

5

Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide.

Sun J, Tang DN, Fu T, Sharma P. Sun J, et al. Among authors: fu t. Cancer Discov. 2012 Feb;2(2):122-30. doi: 10.1158/2159-8290.CD-11-0236. Epub 2011 Dec 27. Cancer Discov. 2012. PMID: 22585857

6

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.

Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Shi LZ, et al. Among authors: fu t. Nat Commun. 2016 Aug 8;7:12335. doi: 10.1038/ncomms12335. Nat Commun. 2016. PMID: 27498556 Free PMC article.

7

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Hailemichael Y, et al. Among authors: fu t. J Clin Invest. 2018 Apr 2;128(4):1338-1354. doi: 10.1172/JCI93303. Epub 2018 Feb 26. J Clin Invest. 2018. PMID: 29480817 Free PMC article.

8

Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.

Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, Wang RF. Voo KS, et al. Among authors: fu t. Cancer Res. 2002 Dec 15;62(24):7195-9. Cancer Res. 2002. PMID: 12499257

9

Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation.

Voo KS, Peng G, Guo Z, Fu T, Li Y, Frappier L, Wang RF. Voo KS, et al. Among authors: fu t. Cancer Res. 2005 Feb 15;65(4):1577-86. doi: 10.1158/0008-5472.CAN-04-2552. Cancer Res. 2005. PMID: 15735048

10

Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.

Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF. Wang HY, et al. Among authors: fu t. J Clin Invest. 2002 Jun;109(11):1463-70. doi: 10.1172/JCI15399. J Clin Invest. 2002. PMID: 12045260 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,970 results

Search Page

Filters